| P/E (FY) | — | Sales (TTM) | $10.8M |
| Earnings (TTM) | -$25.4M | ROE | −40.68% |
| Net Margin | −202.24% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $183.1M | Trading Days | 416 |
| 52W High | 10.15 |
| 52W Low | 4.50 |
| % Off High | −17.14% |
| YTD | 29.38% | 1Y | −13.57% |
| Since incept. (ann.) | 25.61% |
US 66% · CN 34%
| Ann. Volatility (1Y) | 70.66% | Ann. Volatility (3Y) | 78.00% |
| Sharpe (1Y) | 0.14 | Sharpe (3Y) | 0.68 |
| Max Drawdown (1Y) | −54.95% | Max Drawdown (3Y) | −59.96% |
| Beta (3Y, vs SPY) | 1.34 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| VYGR | Voyager Therapeutics, Inc. | $183.7M | — |
| LENZ | LENZ Therapeutics, Inc. | $184.4M | — |
| DTIL | PRECISION BIOSCIENCES INC | $185.0M | — |
| ALGS | Aligos Therapeutics, Inc. | $181.1M | — |
| BCDA | BioCardia, Inc. | $180.0M | — |
| PLX | Protalix BioTherapeutics, Inc. | $187.7M | — |
| CRIS | CURIS INC | $188.3M | — |
| IVVD | Invivyd, Inc. | $174.8M | — |
| ALEC | Alector, Inc. | $168.8M | — |
| ABOS | Acumen Pharmaceuticals, Inc. | $164.7M | — |
| TNYA | Tenaya Therapeutics, Inc. | $164.1M |
| — |
| BCAB | BioAtla, Inc. | $207.7M | — |
